CASE STUDIES

Immuno-Oncology

Identifying rare expertise to add value

Setting the Scene

A leading clinical stage biopharmaceutical company headquartered in Europe, our client is focused on the development of innovative immunotherapies designed to fight infectious diseases and cancer. The company’s immunotherapeutic pipeline is at the forefront of novel cancer treatment strategies that aim to prevent the development of potentially life-threatening tumours at the earliest possible stage.

The Need

Following the success of their lead product’s phase I trial there was an urgent need to appoint a Chief Medical Officer who had the credibility to gain acceptance for their new drug among key opinion leaders when the phase II trial was initiated. This needed to be someone who was a gynaecologist, who had experience of running an international Phase II trial, who was fluent in both English and French and who could be both hands-on and comfortable in such an entrepreneurial environment.

Where to start?

There are not many new gynaecological products in early research and development so this was going to be a very tough challenge and we were searching in a very small pool of likely candidates.

We have a strong track record, however, of finding translational medics for small emerging entrepreneurial biotechs. And the ability to target and identify specific sector expertise particularly where talent is scarce, here in oncology and women’s health, is a strength we have developed through our global networks and rigorous research processes.

The Impact of a Strong Leadership Hire

We recruited a French speaking gynaecologist with complimentary skills sets who also had experience in the oncology and vaccines sector. This appointment enabled the company to complete an IPO a few months after the appointment was made and begin their Phase II trial on time. The company’s immunotherapeutic pipeline is at the forefront of novel cancer treatment strategies that aim to prevent the development of potentially life-threatening tumors at the earliest possible stage.